Claims for Patent: 9,707,303

Summary for Patent: 9,707,303

Title:	Reduction stimulus-responsive gene delivery system and preparation and application thereof
Abstract:	The present invention discloses a gene delivery system containing a reduction-sensitive shielding system having a targeting function, a preparation method and an application in the field of gene therapy thereof. The gene delivery system is composed of a reduction-sensitive shielding system having a targeting function, cationic polymer material and plasmid DNA; the cationic polymer material and the plasmid DNA complexed to form complex particles, the reduction-sensitive shielding system having a targeting function is shielded on the complex surface by means of electrostatic interaction, so as to reduce the toxicity of the delivery system and successfully transfer the loaded genetic material into cells, thereby achieving expression of genetic material and completing the transfection process, and moreover, improving the targeting and the efficiency of gene transfection.
Inventor(s):	Gu; Zhongwei (Sichuan, CN), Nie; Yu (Sichuan, CN), He; Yiyan (Sichuan, CN), Cheng; Gang (Sichuan, CN), Xie; Li (Sichuan, CN)
Assignee:	SICHUAN UNIVERSITY (Chengdu, Sichuan, CN)
Application Number:	14/434,758
Patent Claims:	1. A reduction stimulus-responsive gene delivery system, comprising a shielding system, a cationic polymer material and plasmid DNA, wherein: the cationic polymer material and the plasmid DNA are complexed to form binary complex particles, the shielding system comprises a disulfide bond, and the cationic material comprises a diselenide bond, the shielding system bonds to the surface of the binary complex by means of electrostatic interaction to form ternary complex particles, and the shielding system comprises a glycosaminoglycan derivative having a reduction-sensitive disulfide bond and at least one modified glucuronic acid unit, the at least one modified glucuronic acid unit comprising a moiety containing a carboxyl group linked via said reduction-sensitive disulfide bond. 2. The gene delivery system according to claim 1, wherein the cationic material is at least one of diselenide-conjugated polyethylenimine, polypropyleneimine, spermine, amino acid polypeptide, peptides dendrimer and a peptides dendrimer-containing cationic lipid material. 3. The gene delivery system according to claim 1, wherein the shielding system comprises a hyaluronic acid derivative having a reduction-sensitive disulfide bond and at least one modified glucuronic acid unit, the at least one modified glucuronic acid unit comprising a moiety containing a carboxyl group linked via said reduction-sensitive disulfide bond. 4. The gene delivery system according to claim 1, wherein the cationic material is a diselenide-conjugated oligoethylenimine (OEI-SeSex). 5. A method for preparing the gene delivery system according to claim 1, comprising: 1) dissolving plasmid DNA in sterile water or a sterile HBG buffer (20 mmol 4-hydroxyethyl piperazine-ethanesulfonic acid, 5% glucose) to formulate a DNA solution of a concentration of 0.1 mg/mL; dissolving a cationic material in an HBG buffer to formulate a solution A of a concentration of 0.1 to 10 mg/mL; and dissolving a shielding system in an HBG buffer to formulate a solution B of a concentration of 0.01 to 1 mg/mL; and 2) mixing the solution A obtained in step 1) and a DNA solution, and incubating the mixture for 20 min at room temperature to obtain a binary complex, and then adding the solution B, and incubating the mixture for 20 min at room temperature to obtain a ternary complex. 6. A method for preparing the gene delivery system according to claim 5, comprising: (1) preparation of a reduction-sensitive shielding system having a targeting function: 1) dissolving hyaluronic acid in a phosphate buffer (PBS) at pH 6.8, adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) and 1-hydroxybenzotriazole (HOBT), stirring, and activating the carboxyl group; and adding cystamine dihydrochloride (Cys), and stirring, reacting for 12 h at room temperature, dialyzing the product after the reaction is completed, and freeze-drying, to obtain cystamine grafted hyaluronic acid (HA-Cys); 2) dissolving cystamine grafted hyaluronic acid (HA-Cys) in a phosphate buffer (PBS) of pH 8.5, adding excess amount of dithiothreitol (DTT), reacting for 4 h at room temperature, adjusting the pH value to 3.5 with hydrochloric acid (HCl), adding sodium chloride (NaCl) to a final concentration of 5% (w/v), precipitating with ethanol, and re-dissolving in water, and centrifuging and freeze-drying, to obtain thiolated hyaluronic acid (HA-SH); and 3) dissolving thiolated hyaluronic acid (HA-SH) in a phosphate buffer (PBS), reacting with excess amount of 3-mercaptopropionic acid overnight at room temperature, after the reaction is completed, dialyzing and freeze-drying the product, to obtain a hyaluronic acid (HA-SS--COOH) with disulfide modification and having a terminus being carboxyl group; (2) preparation of a gene delivery system containing the reduction-sensitive shielding system having a targeting function: Dissolving plasmid DNA in sterile water or a sterile HBG buffer, to obtain a DNA solution; dissolving a cationic polymer gene carrier in an HBG buffer, to obtain a solution A; dissolving the reduction-sensitive shielding system having the targeting function (HA-SS--COOH) in an HBG buffer, to obtain a solution B; mixing the DNA solution and the solution B to obtain a complex particles solution of the gene carrier and the plasmid DNA, placing for 20 min at room temperature, and adding the solution B, to obtain the gene delivery system. 7. A complex delivery system, formed by complexing the gene delivery system according to claim 1 and magnetic nanoparticles and/or a pharmaceutically active ingredient. 8. The gene delivery system according to claim 1, wherein the shielding system comprises a hyaluronic acid derivative having the following structure: ##STR00007##

Details for Patent 9,707,303

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2032-10-10